A Study of Trastuzumab in Combination With TS-ONE and Cisplatin in First-line Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer.
Phase of Trial: Phase II
Latest Information Update: 30 Jun 2016
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary) ; Trastuzumab (Primary) ; Cisplatin
- Indications Gastric cancer
- Focus Therapeutic Use
- 01 May 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 28 Nov 2012 Additional lead trial centre and primary endpoint added as reported by ClinicalTrials.gov. (NCT01736410)
- 28 Nov 2012 Planned End Date changed from 1 Dec 2011 to 1 Dec 2012 as reported by ClinicalTrials.gov. (NCT01736410)